statistiche ricercatore

Continente	#
NA - Nord America	904
AS - Asia	241
EU - Europa	200
Continente sconosciuto - Info sul continente non disponibili	64
SA - Sud America	44
AF - Africa	18
Totale	1.471

Nazione	#
US - Stati Uniti d'America	889
SG - Singapore	82
CN - Cina	72
IT - Italia	45
BR - Brasile	37
RU - Federazione Russa	37
SE - Svezia	35
VN - Vietnam	25
HK - Hong Kong	24
DE - Germania	23
GB - Regno Unito	16
FI - Finlandia	13
CI - Costa d'Avorio	11
IN - India	11
BD - Bangladesh	10
FR - Francia	10
CA - Canada	9
BE - Belgio	8
ID - Indonesia	4
MX - Messico	4
CO - Colombia	2
EU - Europa	2
IQ - Iraq	2
LT - Lituania	2
PL - Polonia	2
SA - Arabia Saudita	2
UA - Ucraina	2
A2 - ???statistics.table.value.countryCode.A2???	1
AL - Albania	1
AR - Argentina	1
AT - Austria	1
BF - Burkina Faso	1
BO - Bolivia	1
CL - Cile	1
CR - Costa Rica	1
EC - Ecuador	1
ES - Italia	1
ET - Etiopia	1
GT - Guatemala	1
HU - Ungheria	1
IE - Irlanda	1
JO - Giordania	1
JP - Giappone	1
KE - Kenya	1
KG - Kirghizistan	1
LK - Sri Lanka	1
MZ - Mozambico	1
NL - Olanda	1
OM - Oman	1
PH - Filippine	1
PK - Pakistan	1
RO - Romania	1
SN - Senegal	1
TN - Tunisia	1
TR - Turchia	1
UZ - Uzbekistan	1
VE - Venezuela	1
ZA - Sudafrica	1
Totale	1.410

Nome	#
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study	233
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta	190
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients	184
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort	171
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients	169
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy	163
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis	152
The role of neutralizing antibodies to interferon-β as a biomarker of persistent MRI activity in multiple sclerosis: a 7-year observational study	123
null	65
null	21
Totale	1.471

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	80	0	0	0	2	5	10	4	5	8	11	16	19
2022/2023	146	22	22	8	20	13	13	0	18	21	1	3	5
2023/2024	28	4	7	2	5	3	1	0	2	0	0	0	4
2024/2025	169	12	2	21	12	7	14	20	17	2	7	17	38
2025/2026	383	70	16	24	53	48	19	22	11	40	36	15	29
2026/2027	61	38	13	10	0	0	0	0	0	0	0	0	0
Totale													1.471